Modern combined hormonal therapy in early postmenopause women

• Main Authors: V. B. Mychka, M. Yu. Kirillova, I. V. Kuznetsova, N. A. Voychenko, A. A. Fedorovich, T. V. Balakhonova, Yu. V. Prokhorova, V. A. Vyshivanyuk
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 2012-08-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: metabolic syndrome; arterial hypertension; cardiovascular disease; postmenopause; hormone replacement therapy; drospirenone
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1864

Aim. To study the effects of hormone replacement therapy (HRT) with a combination of estradiol and drospirenone on cardiometabolic risk levels and subclinical vascular pathology among women in early postmenopause. Material and methods. In total, 84 women in early postmenopause, who had given informed consent and underwent a standard examination, were divided into two groups: Group I (with gynaecologist-confirmed indications for HRT with Angeliq (1 mg 17 β-estradiol and 2 mg drospirenone)) and Group II (no HRT). All participants underwent the assessment of metabolic parameters, visceral obesity, intima-media thickness (IMT) of common carotid arteries (CCA), arterial stiffness, and microcirculation (MC) status at baseline and 12 months later. Results. HRT demonstrated beneficial effects on autonomic regulation, lipid metabolism, CCA IMT, and arterial stiffness. It was also associated with a reduction in visceral obesity, some antihypertensive effect, and an increase in the MC dilatation reserve in postmenopausal women. Conclusion. Low-dose combined hormone therapy with drospirenone and estradiol could be recommended to a specific clinical group of women in early postmenopause.